Tianyin Pharmaceutical

Last updated
Tianyin Pharmaceutical Co., Inc.
Type Public
AMEX:  TPI
IndustryHealthcare – Drug Manufacture
Founded1994
Headquarters,
Key people
Guoqing Jiang M.D.
( Chief Executive Officer, Chairman, President, and Chief Accounting Officer )

James Jiayuan Tong M.D., Ph.D.
( Chief Financial Officer, and Director )

Yang Tao

Contents


( Chief Operating Officer ) (Dec 31, 2013)
Servicestraditional Chinese medicine
Revenue $ 62.60M (Dec 31, 2013)
Number of employees
1200 (Dec 31, 2013)

Tianyin Pharmaceutical (AMEX :  TPI) was set up in 1994 and now is based in Cheng Du, China. The company focuses on biopharmaceutical medicines, famous for its generics, traditional Chinese medicines. Most of the products are used in internal medicines, gynecology, hepatology, otolaryngology, urology, neurology, gastroenterology, and orthopedics. Chengdu Tianyin Pharmaceutical Co., Ltd. is the TPI’s subsidiary. [1]

Products and services

In 2010, there were 56 Chinese medicines and pharmaceuticals produced by the company approved by the State Food and Drug Administration (SFDA), 23 of which are listed in the National Medical Reimbursement List (NMRL) and seven are listed in the Essential Drug List (EDL) of China. Nearly half of the medicines are prescription medicines.

Major products are Ginkgo Mihuan Oral Liquid (GMOL, targeting cardiovascular indications), Benorylate Granules, Xiaoyanlidan Tablets, Qijudihuang Mixture, Qianggan Syrup, Kangjunxiaoyan capsule and others. [2]

Research and development

Currently there are 17 products pending SFDA approval and engages in cooperation with many academic institutions in China, such as China Pharmaceutical University, Sichuan University, and Shaanxi University of Chinese Medicines. [3]
In September 2013 Tianyin Pharmaceutical received the Official Certificate of GMP for both of its pre-extraction plant and formulation facilities by the China Food and Drug Administration (CFDA) officials. [4]
July. 2013, the company’s product Gingko Mihuan Oral Liquid (GMOL) was awarded Provincial Essential Drug List (PEDL) status at Guangdong Province. Before that, the company has included in the list in four provinces, namely Henan Province, Shandong Province, Sichuan Province and the City of Chongqing. [5]

Related Research Articles

Sildenafil Medical drug for erectile dysfunction and pulmonary hypertension

Sildenafil, sold under the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is unclear if it is effective for treating sexual dysfunction in women. It is taken by mouth or injection into a vein. Onset is typically within 20 minutes and lasts for about 2 hours.

Good manufacturing practice Manufacturing quality standards

Good manufacturing practices (GMP) are the practices required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of food and beverages, cosmetics, pharmaceutical products, dietary supplements, and medical devices. These guidelines provide minimum requirements that a manufacturer must meet to assure that their products are consistently high in quality, from batch to batch, for their intended use. The rules that govern each industry may differ significantly; however, the main purpose of GMP is always to prevent harm from occurring to the end user. Additional tenets include ensuring the end product is free from contamination, that it is consistent in its manufacture, that its manufacture has been well documented, that personnel are well trained, and that the product has been checked for quality more than just at the end phase. GMP is typically ensured through the effective use of a quality management system (QMS).

Nizatidine

Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease.

TPI may refer to:

National Medical Products Administration

The National Medical Products Administration (NMPA) was founded on the basis of the former State Food and Drug Administration (SFDA). In March 2013, the former regulatory body was rebranded and restructured as the China Food and Drug Administration, elevating it to a ministerial-level agency. In 2018, as part of China's 2018 government administration overhaul, the name was changed to 'National Medical Products Administration' and merged into the newly-created State Administration for Market Regulation. The headquarters are in Xicheng District, Beijing.

The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth USD $110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.

The pharmaceutical industry in Bangladesh is one of the most developed technology sectors within the country. Manufacturers produce insulin, hormones, and cancer drugs. This sector provides 97% of the total medicinal requirement of the local market. The industry also exports medicines to global markets, including Europe. Pharmaceutical companies are expanding their business with the aim to expand the export market.

Chinese patent medicine are herbal medicines in Traditional Chinese medicine, modernized into a ready-to-use form such as tablets, oral solutions or dry suspensions, as opposed to herbs that require cooking.

Food safety in China

Food safety in China is a concern relating to agriculture in the Earth's most populated country. China's principal crops are rice, corn, wheat, soybeans, and cotton in addition to apples and other fruits and vegetables. China's principal livestock products include pork, beef, dairy, and eggs. The Chinese government oversees agricultural production as well as the manufacture of food packaging, containers, chemical additives, drug production, and business regulation. In recent years, the Chinese government attempted to consolidate food safety regulation with the creation of the State Food and Drug Administration of China in 2003; officials have also been under increasing public and international pressure to solve food safety problems. Chinese Vice Premier Li Keqiang said, "Food is essential, and safety should be a top priority. Food safety is closely related to people's lives and health and economic development and social harmony," at a State Council meeting in Beijing.

Yunnan Baiyao

Yunnan Baiyao is a proprietary traditional Chinese medicine marketed and used as an alternative hemostatic product with use in both human and veterinary alternative medicine. The safety and efficacy of Yunnan Baiyao has not been assessed or established by the FDA, European Medicines Agency, or the Australian Therapeutic Goods Administration. There is limited evidence regarding its effectiveness in preventing or treating hemorrhagic and pathological conditions in both humans and animals via oral administration. In a limited number human studies of small sample sizes, administration of Yunnan Baiyao has been shown to correlate with "reduced perioperative bleeding as well as bleeding in various ulcerative–hemorrhagic conditions". A retrospective case-controlled study found Yunnan Baiyao does not delay recurrence of clinical signs or improve survival in dogs with right atrial masses or pericardial effusion. There are multiple routes of drug administration. Yunnan Baiyao is sold in powder, tincture, plaster, paste, aerosol, or tablet form. The medicine, developed by Qu Huangzhang in 1902, is designated as one of two Class-1 protected traditional Chinese medicines which gives it 20 years of trade protection in China. Yunnan Baiyao products are manufactured and distributed by a state-owned enterprise, Yunnan Baiyao Group in Yunnan, China.

Unaffordable medications are a hole in the Chinese safety net. This forces workers to save as much as possible in order to weather family medical emergencies, which acts to depress domestic consumption, leaving no alternative to the traditional unsustainable export and investment driven economic model.

Olainfarm

Olainfarm AS is a Latvian leading manufacturer in the chemical and pharmaceutical sector of the Baltic States.

Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The Company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration (SFDA) to manufacture and sell over 210 other products.

McGuff Companies

The McGuff Companies consist of three entities: a wholesale distributor of medical supplies, a compounding pharmacy, and a pharmaceutical manufacturing facility which produces sterile injectables for national and international distribution. The McGuff Companies have been featured in The International Journal of Pharmaceutical Compounding (IJPC).

Oral administration Route of administration where a substance is taken through the mouth

Oral administration is a route of administration where a substance is taken through the mouth. Per os abbreviated to P.O. is sometimes used as a direction for medication to be taken orally. Many medications are taken orally because they are intended to have a systemic effect, reaching different parts of the body via the bloodstream, for example.

Ipca Laboratories Indian multinational pharmaceutical company

Ipca LaboratoriesLimited is an Indian multinational pharmaceutical company based in Mumbai, India. It produces Theo bromine, Acetylthiophene, and P-Bromo Toluene as Active Pharmaceutical Ingredients (APIs). Ipca sells these APIs and their intermediates world over. It produces more than 150 formulations that include oral liquids, tablets, dry powders, and capsules. The various kinds of drug intermediates that the company manufactures include Theo bromine, Acetylthiophene, and P- Bromo Toluene and promotes over 36 countries of Asia, Africa, CIS, and South America, including Cambodia, Kazakhstan, Kenya, Mauritius, Myanmar, Nigeria, Oman, Russia, Sri Lanka, Sudan, Tanzania, Ukraine, Vietnam and Yemen. The main activities of company are to produce and market pharmaceuticals and drugs. The various products of the company include formulations, drug intermediates, and active pharmaceutical ingredients (API).

Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).

Norbrook Group

Norbrook is a United Kingdom-based pharmaceutical company. It was founded in 1969 by Lord Ballyedmond as Norbrook Laboratories Ltd in Northern Ireland. In 1970, Norbrook began manufacturing of veterinary pharmaceuticals. In 2011 the Norbrook Group was listed by the Belfast Telegraph in its Top 100 Companies list as being in position 28.

Torque pharmaceuticals is an Indian pharmaceutical company with production units at Issapur, Derabassi in Punjab and at Jharmajri, Baddi in Himachal Pradesh. It manufactures medicines for prevention and treatment of various health related problems. The product range comprises antibiotics, nutritional supplements and cough syrup to antipyretics and anti-inflammatory products.

The distribution of medications has special safety and security considerations. Some drugs require cold chain management in their distribution.

References

  1. "Business Summary".
  2. "Company Full Description". Archived from the original on 2010-02-28.
  3. "Company Research and Development".
  4. "TPI Facility Received Official GMP Certificate".
  5. "GMOL Awarded Provincial Essential Drug List (PEDL) Status at Guangdong Province".